SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the immune defects that predispose an individual to persistent coronavirus disease 2019 (COVID-19) remain incompletely understood. In this study, we performed detailed viro-immunologic analyses of a prospective cohort of participants with COVID-19. The median times to nasal viral RNA and culture clearance in individuals with severe immunosuppression due to hematologic malignancy or transplant (S-HT) were 72 and 40 days, respectively, both of which were significantly longer than clearance rates in individuals with severe immunosuppression due to autoimmunity or B cell deficiency (S-A), individuals with nonsevere immunodeficiency, and nonimmunocompromised groups (P < 0.01). Participants who were severely immunocompromised had greater SARS-CoV-2 evolution and a higher risk of developing resistance against therapeutic monoclonal antibodies. Both S-HT and S-A participants had diminished SARS-CoV-2-specific humoral responses, whereas only the S-HT group had reduced T cell-mediated responses. This highlights the varied risk of persistent COVID-19 across distinct immunosuppressive conditions and suggests that suppression of both B and T cell responses results in the highest contributing risk of persistent infection.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Science translational medicine - 16(2024), 731 vom: 24. Jan., Seite eadk1599 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Yijia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 02.04.2024 published: Print-Electronic UpdateOf: medRxiv. 2023 Aug 07;:. - PMID 37577493 Citation Status MEDLINE |
|---|
| doi: |
10.1126/scitranslmed.adk1599 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367565420 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367565420 | ||
| 003 | DE-627 | ||
| 005 | 20240403000118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/scitranslmed.adk1599 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM367565420 | ||
| 035 | |a (NLM)38266109 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Yijia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2023 Aug 07;:. - PMID 37577493 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the immune defects that predispose an individual to persistent coronavirus disease 2019 (COVID-19) remain incompletely understood. In this study, we performed detailed viro-immunologic analyses of a prospective cohort of participants with COVID-19. The median times to nasal viral RNA and culture clearance in individuals with severe immunosuppression due to hematologic malignancy or transplant (S-HT) were 72 and 40 days, respectively, both of which were significantly longer than clearance rates in individuals with severe immunosuppression due to autoimmunity or B cell deficiency (S-A), individuals with nonsevere immunodeficiency, and nonimmunocompromised groups (P < 0.01). Participants who were severely immunocompromised had greater SARS-CoV-2 evolution and a higher risk of developing resistance against therapeutic monoclonal antibodies. Both S-HT and S-A participants had diminished SARS-CoV-2-specific humoral responses, whereas only the S-HT group had reduced T cell-mediated responses. This highlights the varied risk of persistent COVID-19 across distinct immunosuppressive conditions and suggests that suppression of both B and T cell responses results in the highest contributing risk of persistent infection | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Choudhary, Manish C |e verfasserin |4 aut | |
| 700 | 1 | |a Regan, James |e verfasserin |4 aut | |
| 700 | 1 | |a Boucau, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Nathan, Anusha |e verfasserin |4 aut | |
| 700 | 1 | |a Speidel, Tessa |e verfasserin |4 aut | |
| 700 | 1 | |a Liew, May Yee |e verfasserin |4 aut | |
| 700 | 1 | |a Edelstein, Gregory E |e verfasserin |4 aut | |
| 700 | 1 | |a Kawano, Yumeko |e verfasserin |4 aut | |
| 700 | 1 | |a Uddin, Rockib |e verfasserin |4 aut | |
| 700 | 1 | |a Deo, Rinki |e verfasserin |4 aut | |
| 700 | 1 | |a Marino, Caitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Getz, Matthew A |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Mamadou |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Rebecca F |e verfasserin |4 aut | |
| 700 | 1 | |a Tien, Dessie |e verfasserin |4 aut | |
| 700 | 1 | |a Sagar, Shruti |e verfasserin |4 aut | |
| 700 | 1 | |a Vyas, Tammy D |e verfasserin |4 aut | |
| 700 | 1 | |a Flynn, James P |e verfasserin |4 aut | |
| 700 | 1 | |a Hammond, Sarah P |e verfasserin |4 aut | |
| 700 | 1 | |a Novack, Lewis A |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Bina |e verfasserin |4 aut | |
| 700 | 1 | |a Cernadas, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Wallace, Zachary S |e verfasserin |4 aut | |
| 700 | 1 | |a Sparks, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Vyas, Jatin M |e verfasserin |4 aut | |
| 700 | 1 | |a Seaman, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Gaiha, Gaurav D |e verfasserin |4 aut | |
| 700 | 1 | |a Siedner, Mark J |e verfasserin |4 aut | |
| 700 | 1 | |a Barczak, Amy K |e verfasserin |4 aut | |
| 700 | 1 | |a Lemieux, Jacob E |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jonathan Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science translational medicine |d 2009 |g 16(2024), 731 vom: 24. Jan., Seite eadk1599 |w (DE-627)NLM195151879 |x 1946-6242 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:731 |g day:24 |g month:01 |g pages:eadk1599 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/scitranslmed.adk1599 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 731 |b 24 |c 01 |h eadk1599 | ||